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Abstract
Glioblastoma multiforme (GBM) is the most common and malignant of the primary adult brain cancers. Ultrastructural and
biochemical evidence shows that GBM cells exhibit mitochondrial abnormalities incompatible with energy production
through oxidative phosphorylation (OxPhos). Under such conditions, the mitochondrial F0-F1 ATP synthase operates in
reverse at the expense of ATP hydrolysis to maintain a moderate membrane potential. Moreover, expression of the dimeric
M2 isoform of pyruvate kinase in GBM results in diminished ATP output, precluding a significant ATP production from
glycolysis. If ATP synthesis through both glycolysis and OxPhos was impeded, then where would GBM cells obtain high-
energy phosphates for growth and invasion? Literature is reviewed suggesting that the succinate-CoA ligase reaction in the
tricarboxylic acid cycle can substantiate sufficient ATP through mitochondrial substrate-level phosphorylation (mSLP) to
maintain GBM growth when OxPhos is impaired. Production of high-energy phosphates would be supported by glutami-
nolysis—a hallmark of GBM metabolism—through the sequential conversion of glutamine ! glutamate ! alpha-
ketoglutarate! succinyl CoA! succinate. Equally important, provision of ATP through mSLP would maintain the adenine
nucleotide translocase in forward mode, thus preventing the reverse-operating F0-F1 ATP synthase from depleting cytosolic
ATP reserves. Because glucose and glutamine are the primary fuels driving the rapid growth of GBM and most tumors for
that matter, simultaneous restriction of these two substrates or inhibition of mSLP should diminish cancer viability, growth,
and invasion.
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Introduction
Glioblastoma multiforme (GBM) carries the highest mor-
tality rate among primary brain tumors and remains large-
ly unmanageable. Life expectancy following diagnosis is
only about 12 to 14 months. This has changed little for
decades despite continuing research (Fisher and Buffler,
2005; Krex et al., 2007; Stupp et al., 2009; Lawrence et al.,
2011; Ahmadloo et al., 2013; Alexander and Cloughesy,
2017). Indeed, a recent reevaluation found that overall
survival for GBM is woefully similar to that reported by
Cushing almost a century ago (Fatehi et al., 2018). A
defining characteristic of GBM is the secondary structures
of Scherer, which include diffuse parenchymal growth
invasion over the subpial surface, along white matter
tracks, and through the Virchow–Robin spaces (Scherer,
1940; Laws et al., 1993; Kleihues and Ohgaki, 1999;
Zagzag et al., 2008; Shelton et al., 2010c). The highly inva-
sive nature of GBMmakes most current therapies ineffec-
tive (Chang et al., 2005; Krex et al., 2007; Cuddapah et al.,
2014; Perry et al., 2017). Although the introduction of the
toxic alkylating agent, temozolomide, has improved
progression-free survival slightly, quality of life has also
remained poor for most GBMpatients especially for those
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receiving radiation alone (Taphoorn et al., 2005; Stupp
et al., 2009; Flechl et al., 2012).
GBM contains a plethora of morphologically diverse
neoplastic cell types that express neural, glial, and mye-
loid/mesenchymal markers (Rubinstein, 1972; Morantz
et al., 1979; Wood and Morantz, 1979; Roggendorf
et al., 1996; Seyfried, 2001; Yuan et al., 2004;
Huysentruyt et al., 2011; Karsy et al., 2012). Also recog-
nized are abnormalities in the number, structure, and
function of mitochondria in GBM cells (Figure 1).
Several groups have documented GBM cells with
reduced or increased numbers of morphologically abnor-
mal mitochondria with laminations and aberrant or
absent cristae (Sipe et al., 1973; Scheithauer and
Bruner, 1987; Oudard et al., 1997; Arismendi-Morillo
and Castellano-Ramirez, 2008; Katsetos et al., 2013;
Deighton et al., 2014; Feichtinger et al., 2014; Seyfried
et al., 2017). Some mitochondria in human GBM cells
contain few, if any, cristae (Arismendi-Morillo and
Castellano-Ramirez, 2008). In murine GBM, the content
and composition of cardiolipin, the signature lipid of the
mitochondrial inner membrane that regulates oxidative
phosphorylation (OxPhos), exhibit considerable devia-
tions from the normal (Kiebish et al., 2008; Claypool
and Koehler, 2012). A multitude of findings support
the notion that OxPhos is defective in GBM (Lichtor
and Dohrmann, 1986; Feichtinger et al., 2014;
Bartesaghi et al., 2015; Dahlberg et al., 2017). Based on
the concept that mitochondrial structure determines
mitochondrial function (Lehninger, 1964), these multiple
mitochondrial abnormalities, which are of genetic or
environmental origin, would be expected to compromise
effective energy production through OxPhos (Seyfried
and Shelton, 2010; Seyfried et al., 2014, 2015).
In view of the documented abnormalities in GBM
mitochondria, alternative energy source(s) to OxPhos
must be in place to maintain cell viability.
Accumulating evidence indicates that glucose and gluta-
mine are the primary fuels used for driving the rapid
growth of most tumors, including GBM (DeBerardinis
Figure 1. Morphological abnormalities in GBM mitochondria; (a) to (d) (distributed under a Creative Commons license) were repro-
duced from Deighton et al. (2014). The morphology of 150 mitochondria was assessed in six GBM samples and in seven peritumoural
control samples using electron microscopy. (a) Percentage of normal mitochondria where cristae were visible throughout the mito-
chondria in peritumoural control and GBM samples (each bar represents one sample; ***p value¼ .0001); (b) Percentage of abnormal
mitochondria where cristae were sparse and abnormal in peritumoural control and GBM samples (***p value¼ .0001). (c and d)
Representative electron microscopy images of normal and abnormal mitochondria, respectively. The scale bars represent 0.5 mm.
Cristolysis was significantly greater in mitochondria from GBM than from control brain. The possibility cannot be excluded that the
abnormal GBM mitochondria shown in panel (d) originate from areas close to necrotic palisades and might not be representative of
mitochondria in all types GBM cells.
GBM¼ glioblastoma multiforme.
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et al., 2007; Yang et al., 2009). Abundant levels of glu-
cose and glutamine are also available in cyst fluid that is
often present in GBM and could be used as fuel for the
growing tumor cells (Dahlberg et al., 2017). Other poten-
tial metabolic fuels in the tumor microenvironment, for
example, acetate and branched-chain amino acids, are
either not present in sufficient quantities to drive
growth through fermentation or exert nonmetabolic
effects that are yet to be understood (Jaworski et al.,
2016; Seyfried et al., 2017). While amino acids other
than glutamine could also be fuels, they would require
energy for preparation prior to their catabolism (see
later). Glucose drives tumor growth through aerobic fer-
mentation (Warburg effect), whereas glutamine drives
tumor growth through glutaminolysis (Rhodes et al.,
1983; DeBerardinis and Cheng, 2010; Flavahan et al.,
2013; Yang et al., 2017). Metabolism of glucose and glu-
tamine is also responsible for the high antioxidant capac-
ity of the tumor cells, thus making them resistant to
chemo- and radiotherapies (Amores-Sanchez and
Medina, 1999; Xu et al., 2005; Seyfried et al., 2017). It
remains unclear, however, whether glutamine is used pri-
marily as a substrate for citric acid cycle anaplerosis and
lipid synthesis or if it is also used as a major substrate for
energy production through mitochondrial substrate-level
phosphorylation (mSLP). This review describes a frame-
work for how provision of high-energy phosphates
through mSLP could compensate for the loss of energy
production through both glycolysis and OxPhos in
GBM. The information reviewed is derived from a
broad range of experimental materials including human
glioma tissue, validated preclinical models of GBM, and
cultured glioma cell lines. Advantages and disadvantages
associated with some of the models systems were pre-
sented previously (Seyfried, 2012c; Seyfried et al., 2014).
Role of Glucose and Glycolysis in GBM
Energy Metabolism
Warburg originally proposed that cancer originated from
an irreversible damage to cellular respiration that was fol-
lowed by a gradual increase in fermentation, that is, glu-
cose metabolized through glycolysis, leading to excessive
formation of lactate (Warburg, 1956a). The increased fer-
mentation, which was present even in saturating partial
pressures of oxygen, was necessary to compensate for a
loss of energy through OxPhos. Aerobic fermentation is
also a metabolic hallmark of GBM (Kirsch et al., 1972;
Rhodes et al., 1983; Lichtor and Dohrmann, 1986;
Oudard et al., 1997; Roslin et al., 2003). Despite the afore-
mentioned evidence showing that mitochondria are
abnormal in GBM tumor tissue, some investigators have
claimed that mitochondria and OxPhos are normal in
GBM and other brain tumor types based mostly,
but not exclusively, on in vitro studies of oxygen consump-
tion rates in tumor cells (Elstrom et al., 2004; Wise et al.,
2008; Pike et al., 2011; Zhou et al., 2011; Janiszewska
et al., 2012; Marin-Valencia et al., 2012; Ward and
Thompson, 2012; Yang et al., 2014; Maximchik et al.,
2016). It is not clear how these findings can be reconciled
in light of the abnormalities reported in the number, struc-
ture, and function of GBM mitochondria obtained from
GBM tissue sections (referenced earlier). Discrepancies
between in vivo and in vitro studies related to mitochon-
drial structure and function were not discussed in most of
these studies. Warburg also proposed that oxygen con-
sumption could be similar in tumor cells and normal
cells but that ATP output from respiration would be less
in the former than in the latter.
Despite the widely held view that oxygen consumption
in cultured cells is a biomarker for OxPhos activity, many
studies have since established that oxygen consumption is
not linked to OxPhos ATP output in various tumor cell
lines (Arcos et al., 1969; Ramanathan et al., 2005; Hall
et al., 2013; Leznev et al., 2013; Pacini and Borziani,
2016). It is not possible, however, to exclude a complete
absence of OxPhos in tumor cells, as Hall et al. (2013)
showed that coupling was reduced by about 50% even in
an extreme case of V600EBRAF-induced OxPhos dys-
function in melanoma cells. It is important to emphasize,
however, that a 50% reduction in OxPhos would dissi-
pate the protonmotive force and cause reversal of the
F0-F1 ATP synthase (Chinopoulos, 2011a, 2011b). The
F0-F1 ATP synthase generally operates in forward mode
(i.e., generating ATP) only when mitochondria are suffi-
ciently polarized. It would not be possible for the F0-F1
ATP synthase to generate ATP under a loss of electron
transport chain (ETC) operation on the order of 45% to
50% and would actually hydrolyze ATP, pumping pro-
tons out of the matrix. Reversal of the ATP synthase is
what affords mSLP the critical role of providing ATP
directly within the matrix when OxPhos becomes inhib-
ited or impaired. These considerations are further
addressed in the section below on, Role of Adenine
Nucleotide Translocase and F0-F1 ATP synthase in
GBM. Furthermore, the possibility of an inverse rela-
tionship between OxPhos efficiency and tumor aggres-
sion has been reported (Solaini et al., 2011). Warburg
and Burk also described a similar phenomenon with
respect to the degree of fermentation and tumor
growth, that is, the more aggressive is the cancer, the
greater is the fermentation (Warburg, 1956a; Burk
et al., 1967). It is also documented that estimates of mito-
chondrial OxPhos efficiency can differ between in vivo
and in vitro environments (Suarez et al., 1991; Kiebish
et al., 2009). Viewed collectively, these studies indicate
that oxygen consumption alone cannot be used as a mea-
sure of normal respiration in cultured cells including
GBM cells.
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Another misconception comes from findings that aer-
obic glycolysis is required not only for GBM cell prolif-
eration but also for proliferation of nontransformed cells
grown in vitro, thus giving the impression that aerobic
glycolysis is a normal phenomenon of cell proliferation
(Vander Heiden et al., 2009). This phenomenon does not,
however, occur in proliferating nontransformed cells
grown in vivo, for example, regenerating liver cells and
normal colon cells, which use fatty acids and butyrate as
fuel, respectively (Warburg, 1956a; Simek and Sedlacek,
1965; Hague et al., 1997; Thevananther, 2010). We also
showed that the in vitro growth environment suppresses
Complex I activity and forces normal astrocytes to fer-
ment through a Crabtree-linked effect (Kiebish et al.,
2009). This in vitro effect would obscure differences in
energy metabolism between normal brain cells and
GBM cells. Indeed, Warburg and Burk cautioned against
generalizations made on cellular energy metabolism
based solely on in vitro studies (Burk and Schade, 1956;
Warburg, 1956a, 1956b). It is glucose and not lactate that
primarily drives brain energy metabolism (Allen et al.,
2005; Dienel, 2012; Nortley and Attwell, 2017), making
it unlikely that lactate could serve as a major energy
metabolite for neoplastic GBM cells with diminished
OxPhos capacity. A continued production of lactate in
the presence of saturating partial pressures of oxygen is
indicative of an impaired Pasteur effect, which itself
could be linked to respiratory impairment (Racker,
1974). Proliferation is the default state of metazoan
cells and, together with fermentation, was the dominant
phenotype of all cells in the alpha period before oxygen
entered the atmosphere (Szent-Gyorgyi, 1977;
Sonnenschein and Soto, 2000). Respiratory impairment
or inhibition, arising from either genetic or environmen-
tal causes, could thus force cells into a fermentation
metabolism with consequent proliferation (Seyfried and
Shelton, 2010).
While it is well recognized that biochemical pathways
are reprogramed in GBM and in other cancers (Vander
Heiden et al., 2009; Ward and Thompson, 2012), it
remains unclear how GBM cells would generate sufficient
energy with the documented abnormalities in their mito-
chondria. A reanalysis of how tumor cells obtain energy
and metabolites for growth can help elucidate the origin
of energy synthesis in GBM. The rate of glycolysis is
increased in GBM, which is necessary for supporting
growth under hypoxic conditions that commonly occur
in the interior of the tumor mass (Roslin et al., 2003),
shuttling glycolytic intermediates for building blocks of
new cells. The upregulation of this pathway is due in part
to hypoxia-induced stabilization of hypoxia-inducing
factor 1a (HIF-1a), which amplifies the transcription of
genes encoding glucose transporters and glycolytic
enzymes (Semenza, 2010). Oncogenic signaling pathways,
including phosphoinositide 3-kinase, can activate HIF-1a
under normoxic conditions (Plas and Thompson, 2005).
Mutations in tumor suppressor proteins such as the von
Hippel–Lindau tumor suppressor gene product (Kaelin,
2008), succinate dehydrogenase (SDH; Selak et al., 2005),
and fumarate hydratase (FH) can also activate HIF-1a
(King et al., 2006). Due to the cellular heterogeneity of
GBM, it is likely that individual cells harbor one or more
of these mutations (Soeda et al., 2015). It should also be
recognized that the upregulation of oncogenes in GBM
and most other cancers is necessary to facilitate
substrate-level phosphorylation when OxPhos becomes
unable to maintain the differentiated state (Seyfried
et al., 2014). Relevant to this, dysregulated tumor cell
growth and oncogene expression are often abolished
when the cancer nucleus is placed in a cytoplasm contain-
ing normal mitochondria or when normal mitochondria
replace tumor mitochondria in the cytoplasm (Seyfried,
2012b, 2012e; Kaipparettu et al., 2013; Seyfried, 2015).
These findings indicate that normal mitochondrial func-
tions can downregulate oncogenic signaling pathways
restoring normal metabolic programing regardless of
the genetic abnormalities present in the tumor cells.
Indeed, recent findings of cancer driver mutations in
normal cells seriously challenge the role of somatic muta-
tions in the origin of cancer (Martincorena et al., 2018)
including in the brain (Nishioka et al., 2018 and referen-
ces therein).
The enhanced use of glucose is thought to provide
essential intermediates for tumor cell growth and prolif-
eration by diverting metabolites into the pentose phos-
phate pathway (Icard and Lincet, 2012), as well as
providing intermediates for lipid synthesis, the hexos-
amine pathway, and the synthesis of uridine diphosphate
glucose (Vander Heiden et al., 2009). More recently, it
was shown that breast cancer cells could maintain rapid
growth and proliferation by diverting 3-phosphoglycer-
ate from glycolysis to generate serine and glycine through
phosphoglycerate dehydrogenase (PHGDH; Possemato
et al., 2011). Interestingly, suppression of PHGDH
expression decreased cell proliferation but did not
affect intracellular serine levels. On the other hand,
reduced PHGDH expression was associated with reduced
levels of a-ketoglutarate (Possemato et al., 2011), the
main precursor for mSLP (see later). This mechanism
also appears to operate in GBM (Liu et al., 2013).
It should also be recognized that blood glucose levels
are directly correlated with GBM growth, that is, the
higher the blood glucose, the faster the growth and less
the survival, while the lower the blood glucose, the slower
the growth and the greater the survival (Seyfried et al.,
2003; McGirt et al., 2008; Derr et al., 2009; Mayer et al.,
2014; Tieu et al., 2015).
In tumor cells, glycolytic intermediates escape leak-
down toward pyruvate formation and subsequent entry
into the mitochondria, being shunted toward the
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aforementioned subsidiary pathways by the preferential
expression of the M2 isoform of pyruvate kinase
(PKM2). Pyruvate kinase (PK) catalyzes the rate-
limiting, ATP-generating payoff step of glycolysis in
which phosphoenolpyruvate (PEP) is converted to pyru-
vate (Mazurek et al., 2005). Multiple isoenzymes of PK
exist in mammals. The type L is found in liver and kid-
neys, the type R in erythrocytes, type M1 in muscle and
brain, and type M2 in embryonic and adult stem cells
(Mazurek et al., 2005). GBM cells appear to switch
from the PKM1 to PKM2 isoform (Desai et al., 2014).
Unlike PKM1, which promotes glycolysis and rapid
energy generation, PKM2 may attain a dimeric form
that exhibits low affinity to its substrate PEP rendering
it inactive at physiological PEP concentrations (Christofk
et al., 2008). The high GBM cellular heterogeneity makes
it difficult to deduce with certainty, which cells exhibit the
dimeric versus tetrameric PKM2 form (Marin-Valencia
et al., 2012; Desai et al., 2014; Soeda et al., 2015).
Preferential expression of PKM2 over PKM1 is mediated
by modulating exon splicing, promoted by the oncopro-
tein Myc (David et al., 2010). HIF-1a also induces tran-
scription of PKM2, but not PKM1, and PKM2 serves as
a cotranscriptional activator of HIF-1a, mediated by the
proline hydroxylase PHD3 (Luo et al., 2011). A major
paradox regarding PKM2 is that cells expressing it pro-
duce more glucose-derived pyruvate than PKM1-
expressing cells, despite the diminished activity of the
M2 isoenzyme compared with M1. One way to achieve
this is through a proposed alternative glycolytic pathway
involving an enzymatic activity not yet purified that
dephosphorylates PEP to pyruvate, without generating
ATP (Vander Heiden et al., 2010). Alternatively, the
decreased enzymatic activity of PKM2 promoting accu-
mulation of 3-phosphoglycerate may serve as an entry
point for serine synthesis. In this pathway, serine dehy-
dratase can directly convert serine to pyruvate (Ward and
Thompson, 2012). Most recently though, PKM2 was
reported to localize to the nucleus activating transcrip-
tion of MEK5, a protein kinase that belongs to theMAP
kinase kinase family involved in growth factor-stimulated
cell proliferation, using PEP as a phosphate donor (Gao
et al., 2012). The latter study highlighted an important
link between altered metabolism and gene expression in
carcinogenesis and created a precedent for considering
roles of metabolic intermediates other than those partic-
ipating in classical biochemical pathways.
The fate of pyruvate in GBM is mostly conversion to
lactate, by lactate dehydrogenase (LDH), rather than
entry into mitochondria (see later). LDH is a tetramer
composed of two different subunits, LDHA and LDHB,
which can assemble into five different combinations
(Markert et al., 1975). Augmented expression of Myc-
mediated LDHA is a hallmark of many tumors, the
majority of which are highly glycolytic and are associated
with a poor prognosis (Dang et al., 2008; Koukourakis
et al., 2009). LDHA is the predominant isoform in GBM
and most other malignant cancers (Moreno-Sanchez
et al., 2009; Li et al., 2016). The association of LDHB
with cancer is more complex (Doherty and Cleveland,
2013) and is not likely to play a major role in GBM
growth. LDHA catabolizes pyruvate to lactate producing
NADþ, which is necessary to drive glycolysis by GAPDH
(Dawson et al., 1964; Li et al., 2016). The reaction cata-
lyzed by the cytosolic malate dehydrogenase (MDH1)
was also recently shown to contribute to NADþ provi-
sion (Gaude et al., 2018). Furthermore, lactate acidifies
the tumor microenvironment (Fantin et al., 2006; Gillies
et al., 2008), which enhances the activity of several proin-
vasive factors (Gimenez-Roqueplo et al., 2008; Parks
et al., 2013). Recent studies show, however, that it is
carbonic anhydrase, and not LDH, that is mostly respon-
sible for tumor-induced acidification (Swietach et al.,
2014). Nonetheless, lactate efflux provokes a local inflam-
matory response attracting macrophages that secrete
cytokines and growth factors promoting tumor cell
growth and metastasis (Seyfried, 2001; Estrella et al.,
2013). The importance of LDHA activity in acidifying
the microenvironment and creating a local inflammatory
response, together with the provision of NADþ for
GAPDH regarding tumor survival, is reflected by the
fact that LDHA inhibitors are becoming promising anti-
tumor agents (Billiard et al., 2013; Doherty and
Cleveland, 2013; Li et al., 2016). Relevant to this, down-
regulation of LDHA in gliomas with mutations in isoci-
trate dehydrogenase (IDH) appeared responsible for slow
growth and better prognosis (Chesnelong et al., 2014).
This was probably mediated by increased methylation
of the LDHA promoter because silencing of LDHA in
brain tumor stem cells exhibiting mutations in IDH was
associated with slower growth (Chesnelong et al., 2014).
Fantin et al. (2006) and Li et al. (2016) also found that
silencing LDHA could reduce tumor progression.
Furthermore, Zhang et al. (2016) showed that additional
epigenetic reprogramming, including immune-related
genes, is likely to be involved in the pathogenesis of gli-
omas exhibiting mutations in IDH. IDH mutant glioma
cells acquire resistance to natural killer (NK) cells
through epigenetic silencing of NKG2D ligands.
Role of Pyruvate Dehydrogenase Complex
and Pyruvate Carboxylase in GBM
Pyruvate has three fates following entry into the
mitochondria in normal cells, (a) conversion to oxaloac-
etate by pyruvate carboxylase (PC), (b) conversion to
acetyl-CoA by the pyruvate dehydrogenase complex
(PDHC), and (c) transamination with glutamate to
a-ketoglutarate and alanine by a mitochondrial alanine
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aminotransferase. In GBM cells, however, both PDHC
and PC are usually downregulated (Cheng et al., 2011;
Yuen et al., 2016). HIF-1a, Myc, and other tyrosine kin-
ases activate pyruvate dehydrogenase kinases (PDKs),
which phosphorylate and thus inactivate the mitochon-
drial PDHC (Papandreou et al., 2006). PC activity is
suppressed in several cancer cell types (Chang and
Morris, 1973), including glioma cells (Portais et al.,
1993). Accordingly, PC is induced only when tumors
grow in a glutamine-independent manner (Cheng et al.,
2011). Inhibition of mitochondrial pyruvate catabolism is
critical for tumor survival. Inhibition of PDK1 activates
PDHC, with dichloroacetate, a drug used for the treat-
ment of hereditary lactic acidosis. This then results in
suppression of tumor growth in vitro and in vivo
(Michelakis et al., 2008). In GBM, due to the high cellu-
lar heterogeneity, pyruvate metabolism through PDHC
and PC exhibits cell-dependent variability (Marin-
Valencia et al., 2012). However, the consensus is that
PDHC, an NADþ and CoASH-requiring enzyme com-
plex, and PC, an ATP-hydrolyzing enzyme, are down-
regulated in cancer mitochondria. We discuss in the
following sections how downregulation of PDHC free
up CoASH for a-ketoglutarate dehydrogenase complex
(KGDHC), a critical reaction by which mSLP produces
high-energy phosphates through glutaminolysis.
From the earlier considerations, it is evident that pyru-
vate metabolism by mitochondria is limited in GBM and
that the high glycolytic rate may not generate adequate
amounts of ATP due to a hindered payoff phase. This
concept is depicted in Figure 2. Accordingly, the high
glycolytic rate seen in GBM is needed more for rapid
synthesis of growth metabolites than for ATP synthesis.
Relevant to this, no alternative cytosolic pathways are
known that could generate sufficient ATP to replace
energy loss through glycolysis and OxPhos.
Role of Citrate Metabolism in GBM
Acetyl-CoA is required for the cytosolic synthesis of fatty
acids, cholesterol, and isoprenoid synthesis (Wakil et al.,
1957). Acetyl-CoA cannot be directly exported to the
cytoplasm but instead must first condense with oxaloac-
etate to form citrate through citrate synthase. Citrate is
then converted to either isocitrate by aconitase (ACO2)
or is exported to the cytosol where it is catabolized to
acetyl-CoA and oxaloacetate by ATP-citrate lyase
(ACL), at the expense of a high-energy phosphate bond
provided by ATP. Acetyl-CoA is subsequently carboxyl-
ated to malonyl CoA also at the expense of a high-energy
phosphate bond provided by ATP, initiating lipogenesis
(Stryer, 1995). The importance of ACL is not only to
catabolize citrate for the purpose of yielding acetyl-
CoA, the building block for lipid synthesis in the cyto-
plasm, but also to decrease the concentration of citrate,
which is a major negative allosteric modulator of phos-
phofructokinase, a rate-limiting step of glycolysis (Stryer,
1995). Akt facilitates the appearance of acetyl-CoA in the
cytosol by phosphorylating and activating ACL (Berwick
et al., 2002). Pharmacologic inhibition or silencing of
ACL or acetyl-CoA carboxylase or fatty acid synthase
decreases proliferation of cancer cells (Swinnen et al.,
2006), and especially GBM (Lin et al., 2010; Lee et al.,
2012; Poteet et al., 2013). It is important to mention,
however, that ACL is likely to have little importance in
GBM, as GBM cells can acquire fatty acids from the
microenvironment, thus bypassing an essential need for
fatty acid synthesis (Ta and Seyfried, 2015). However,
many cancer cells exhibit a downregulation in the activity
of PDHC, which results in diminished provision of
acetyl-CoA in the mitochondrial matrix. In aggregate,
it can be deduced that in GBM mitochondria, upregula-
tions of ACL and acetyl-CoA carboxylase demand an
adequate pool of cytosolic ATP.
Role of IDH in GBM
IDH exhibits three isoforms IDH1, NADPþ-dependent
isocitrate dehydrogenase (IDH2), and IDH3. IDH1 and
IDH2 are homodimeric enzymes found in the cytoplasm
and mitochondria, respectively, and produce NADPH.
IDH1 and IDH2 are highly homologous but structurally
and functionally distinct from the intramitochondrial
IDH3, which produces NADH (Stryer, 1995).
Many GBM cells exhibit reductive carboxylation of
a-ketoglutarate to isocitrate by reversal of IDH and fur-
ther isomerisation to citrate by ACO2, a pathway that
was described in the early metabolic literature (Ochoa,
1948) and has been investigated as a way to produce cit-
rate for the purpose of lipogenesis from a-ketoglutarate
derived from glutamine (Wise et al., 2011). Furthermore,
specific mutations in IDH1 and IDH2 are linked to
tumorigenesis, in particular, GBM and acute myeloid
leukemia (Yan et al., 2009), but not other tumors
(Bleeker et al., 2009). It was shown that these mutations
confer to IDH1 and IDH2 the ability to convert a-keto-
glutarate to 2-hydroxyglutarate (2-HG) in a NADPH-
dependent manner (Dang et al., 2009; Ohka et al.,
2014). Conversion of a-ketoglutarate to 2-HG could
lower ATP production, as a-ketoglutarate would be
needed as a substrate for mSLP (see later). As also dis-
cussed earlier, reduced a-ketoglutarate levels and LDHA
silencing could explain in part the more favorable prog-
nosis for those GBM patients harboring IDH mutations
(Chesnelong et al., 2014).
Role of Glutamine Metabolism in GBM
Substantial evidence exists documenting an important
role for glutaminolysis and glutamine in cancer and
6 ASN Neuro
specifically in GBM (Newsholme and Board, 1991;
Medina, 2001; Yuneva, 2008; DeBerardinis and Cheng,
2010; Zhang et al., 2014; Liu et al., 2017; Maus and
Peters, 2017; Oizel et al., 2017; Lemberg et al., 2018).
Since the 1950s, it was recognized that tumors require
large amounts of glutamine for growth and survival
(hence the inclusion of glutamine in most culture
media). The high-affinity glutamine transporter Slc1a5
(ASCT2) is upregulated in multiple types of cancer
including GBM and has been implicated in mediating
net glutamine uptake (Sidoryk et al., 2004; Fuchs and
Bode, 2005). Even in the early studies, it was deduced
that the high rate of glutamine consumption could not
be fully accounted by protein synthesis because it
exceeded the need for essential amino acids by an order
of magnitude (Eagle et al., 1956). Several decades later, it
was recognized that glutamine is a major energy source in
tumor cells including GBM (Reitzer et al., 1979;
Rossignol et al., 2004). The interconversion of glutamine
and glutamate is bidirectional in normal cells, with
Figure 2. Energetics of glycolysis and OxPhos in normal tissue (a) versus GBM (b). In GBM, the diminished activity of dimeric PKM2 to
generate ATP yields a net 0 ATP output from glycolysis. Also, because GBM mitochondria exhibit a dysfunctional ETC and a reverse-
operating F0-F1 ATP synthase, they are ATP consumers (0 ATP output). OxPhos in GBM mitochondria may operate at a diminished rate,
and this is depicted by the gray-dashed arrows traversing complexes I, III, and IV implying diminished ability for proton expulsion.
FADH¼ reduced form of flavin adenine dinucleotide; GBM¼ glioblastoma multiforme; GPI¼ phospohexose isomerase; HK¼ hexokinase
(any isoform); LDH¼ lactate dehydrogenase; PEP¼ phosphoenolpyruvate; PFK¼ phosphofructokinase; PGK¼ phosphoglycerate kinase;
PK¼ pyruvate kinase; PKM2¼ pyruvate kinase M2 isoform, dimeric; BPG¼ biphosphoglycerate; 3-PG¼ 3-phosphoglycerate.
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glutamine synthetase catalyzing glutamine formation. In
tumors, however, overexpression of glutaminases and
suppression of glutamine synthetase favor the forward
reaction toward glutamate (Perez-Gomez et al., 2005).
Glutaminase activity correlates well with tumor growth
rates in vivo (Knox et al., 1969), especially for GBM
(Shelton et al., 2010b; Panosyan et al., 2016).
Glutaminase activity is critically important for GBM,
as glutaminase and glutamate levels are elevated follow-
ing treatment with mTOR kinase inhibitor (Perez-Gomez
et al., 2005). Glutamine-derived glutamate also facilitates
GBM invasion (Takano et al., 2001). We also proposed
that the most invasive cells of GBM are derived from
neoplastic microglia/macrophages, which depend heavily
on glutamine for growth (Huysentruyt et al., 2011).
Moreover, a decrease in glutaminase activity diminishes
growth rates of many tumor cells including the metastatic
VM-M3 GBM model (Shelton et al., 2010b).
Implantation of tumor tissue triggers a rapid increase
in muscle glutamine output and a drop in muscle gluta-
mine stores in rodents (Parry-Billings et al., 1991).
A similar burden has been suggested to occur in human
tumors (Souba, 1993). The consistency of high glutamine
uptake in many tumors led to the development of gluta-
mine PET tracers showing promise for the imaging of
glutaminolysis (Wang et al., 2010; Qu et al., 2012).
Although glutamine, like glucose, is a major energy
metabolite for GBM, the mechanism by which glutamine
generates energy remains unclear especially in tumor cells
with abnormalities in the number, structure, and function
of their mitochondria.
Some have suggested that GBM cells predominantly
oxidize acetate rather than glutamine for growth (Marin-
Valencia et al., 2012; Mashimo et al., 2014). As both
acetate and glutamine pass through the common
KGDHC! succinate-CoA ligase (SUCL)! SDH path-
way (see later), it remains to be resolved how acetate, but
not glutamine, is catabolized to citric acid cycle inter-
mediates. Relevant to this, acetate has been implicated
as an epigenetic regulator of posttranslational protein
modification and might actually have therapeutic poten-
tial in cancer management (Jaworski et al., 2016). Thus,
the role of acetate in GBM metabolism remains unclear.
The fate of glutamine in normal and tumor cells varies
widely. An active synthesis of nitrogen-containing com-
pounds, specifically nucleotides and nonessential
amino acids (NEAAs), is required for tumor growth.
Glutamine is the obligate nitrogen donor in at least
three independent steps for purine synthesis including
phosphoribosylpyrophosphate amidotranferase, phos-
phoribosylformylglycinamidine synthetase, and GMP
synthetase. Glutamine is also important in two indepen-
dent enzymatic steps for pyrimidine synthesis, carbamoyl
phosphate synthetase II and CTP synthetase (Ahluwalia
et al., 1990; Young and Ajami, 2001). Glutamine-derived
glutamate is the primary nitrogen donor for the synthesis
of NEAAs including asparagine (Ahluwalia et al., 1990).
This is interesting because asparagine is considered a
growth metabolite for GBM and other tumors
(Panosyan et al., 2017; Knott et al., 2018). The
glutamine:fructose-6-phosphate amidotransferase reac-
tion transfers the amide nitrogen of glutamine to form
glucosamine-6-phosphate, a precursor for N-linked and
O-linked glycosylation needed for hexosamine synthesis
(DeBerardinis and Cheng, 2010). Although some have
considered that glutamine can be metabolized to lactate
through the malic enzyme to produce NADPH for lipid
biosynthesis (Qu et al., 2012), other findings indicate that
little glutamine is metabolized to lactate in GBM and in
other tumor cells (Ta and Seyfried, 2015).
In addition to the previous reactions, glutamine also
participates in the synthesis of glutathione (GSH)
through GSH cysteine ligase, thus playing a major role
in the maintenance of cellular redox homeostasis
(Amores-Sanchez and Medina, 1999; Le et al., 2012).
GSH comprises glutamate, cysteine, and glycine.
Glutamate contributes to the uptake of cystine (Sato
et al., 1999). Cystine can then be converted to cysteine
inside the cell and used in GSH synthesis (Stryer, 1995).
In addition, glutamine induces synthesis of manganese
superoxide dismutase (Aiken et al., 2008), another pow-
erful antioxidant system in mitochondria of GBM (Ria
et al., 2001; Shwetha et al., 2016). Hence, glucose and
glutamine metabolism can protect GBM from oxidative
stress, thus making GBM resistant to radio- and chemo-
therapy (Seyfried et al., 2017).
It is our view that glutamine not only provides nitro-
gen for synthesis of nucleotides and NEAAs but also
provides a-ketoglutarate to serve as a precursor for
ATP synthesis through substrate-level phosphorylation
in the citric acid cycle. Relevant to this, it has been
recently demonstrated that in fibroblasts from a
patient with SUCL deficiency, glutamine oxidation was
impaired (Chinopoulos et al., 2018). The availability of
a-ketoglutarate may occur either through the glutamate
dehydrogenase (GLUD1) reaction or through the trans-
amination reaction (DeBerardinis and Cheng, 2010).
Indeed, cells from GBM and other cancers rely on
either GLUD1-mediated glutamate deamination (Sato
et al., 1999) or transamination (Weinberg et al., 2010),
thus providing a-ketoglutarate to the cycle. In at least
one study, glutamate derived by transamination was sug-
gested to be the major route (Moreadith and Lehninger,
1984). Furthermore, selective inhibition of glutamate
transamination with aminooxyacetic acid hindered
tumor growth in the absence of nonspecific toxicity of
complete inhibition of glutamine metabolism involving
GLUD1 (Wise et al., 2008). Oncogenic signals originat-
ing from Myc and perhaps also Ras induce all of the
previously mentioned pathways involved in glutamine
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entry and ensuing glutaminolysis in tumor cells
(DeBerardinis et al., 2007; Weinberg et al., 2010).
Overall, it can be concluded that the mitochondria in
GBM cells strongly depend on glutamine as a source of
a-ketoglutarate that can be used for energy production
through mSLP.
Role of the KGDHC in GBM
The KGDHC consists of multiple copies of three subu-
nits: a-ketoglutarate dehydrogenase, dihydrolipoyl succi-
nyltransferase, and dihydrolipoyl dehydrogenase. It
catalyzes the conversion of a-ketoglutarate, CoASH,
and NADþ to succinyl-CoA, NADH, and CO2 and
exhibits a high flux control coefficient in the generation
of reducing equivalents and succinyl CoA (Sheu and
Blass, 1999; Kiss et al., 2013). The PDHC and the
KGDHC compete for the same pool of CoASH and
NADþ (Kiselevsky et al., 1990). Even a small decrease
in KGDHC activity will lead to a considerable decrease
in substrate-level phosphorylation in the mitochondrial
matrix (Chinopoulos et al., 2010; Kiss et al., 2013, 2014).
Hence, the diversion of a-ketoglutarate to 2-hydroxyglu-
tarate could explain in part the improved overall survival
of GBM patients containing the IDH mutations, as this
diversion would reduce ATP synthesis through mSLP,
thus reducing tumor growth.
Apart from tumor metabolism under ischemia or hyp-
oxia, there is mounting evidence of pronounced conver-
sion of a-ketoglutarate to succinate (Hochachka et al.,
1975), implying that KGDHC remains operational
(Chinopoulos, 2013). However, during anoxia, when
the ability of Complex I to oxidize NADH to NADþ is
impaired, the question arises as to the origin of NADþ
for the KGDHC reaction. Under these conditions, we
recently reported that mitochondrial diaphorases oxidize
matrix NADH supplying NADþ to KGDHC (Kiss et al.,
2014; Ravasz et al., 2018). Furthermore, we showed
that Complex III of the respiratory chain mediated reox-
idation of the reducible substrates for the diaphorases
using endogenous quinones (Kiss et al., 2014).
Regarding KGDHC and cancer, it can be deduced that
in hypoxia/anoxia, when the rate of NADH oxidation by
Complex I is reduced, mitochondrial diaphorases
use endogenous quinones to regenerate NADþ for
the KGDHC reaction. This raises the possibility that
downstream provision of succinyl CoA by KGDHC
maintains substrate-level phosphorylation yielding ATP
or GTP in the mitochondrial matrix. We now propose
that mSLP provides the majority of energy needed to
drive GBM growth. This concept was originally sug-
gested for the VM-M3 murine glioblastoma cells
(Seyfried, 2012d).
Role of SUCL
SUCL is a heterodimeric enzyme, composed of an
invariant a subunit encoded by SUCLG1 and a
substrate-specific b subunit, encoded by either
SUCLA2 or SUCLG2. This dimer combination results
in either an ATP-forming (EC 6.2.1.5) or a GTP-
forming SUCL (EC 6.2.1.4). The enzyme catalyzes the
conversion of succinyl-CoA and ADP (or GDP) to
CoASH, succinate, and ATP (or GTP). The DG’ for
this reaction is 0.07 kJ/mol, and it is reversible (Li
et al., 2013). When SUCL proceeds in the direction
toward succinyl-CoA, this product may follow heme-
or ketone body metabolism (Ottaway et al., 1981). On
the other hand, the reaction proceeding toward ATP or
GTP formation is termed substrate-level phosphorylation
and can occur in the presence or absence of oxygen.
Substrate-level phosphorylation during anoxia/ischemia
rescues cells from cytosolic/nuclear ATP depletion.
Moreover, this mechanism prevents mitochondria from
reverting to ATP consumption by shifting the reversal
potential (the mitochondrial membrane potential—
DWm—value at which there is no net transfer of
ADP-ATP across the inner mitochondrial membrane)
of the adenine nucleotide translocase (ANT) toward
more negative values than the DWm (Chinopoulos,
2013; Kiss et al., 2013, 2014). Relevant to this, matrix
inorganic phosphate activates SUCL and thus contrib-
utes to the anaerobic provision of ATP synthesis in
mitochondria (Phillips et al., 2009). GTP is a central
regulator of cellular anabolism (Pall, 1985) and is used
in mitochondria by the protein synthesis machinery, the
PEP carboxykinase isoform 2, the GTP-AMP phospho-
transferase, and by other GTP-binding proteins
(Thomson, 1998). GTP-forming SUCL may support
ATP formation in the matrix through the concerted
action with a mitochondrial isoform of a nucleotide
diphosphate kinase known as nm23-H4. This kinase
complexes with either an ATP- or GTP-forming
SUCL (Kadrmas et al., 1991; Kowluru et al., 2002)
and plays a role in the maintenance of mtDNA
(Suomalainen and Isohanni, 2010). Interestingly,
nm23-H4 was recently reported to exhibit a moonlight-
ing function involving intermembrane lipid transfer
operated by cardiolipin (Schlattner et al., 2013). This
property affords to the enzyme a regulatory role in
lipid signaling of apoptosis. SUCL is not a critical
enzyme in all tissues; for example, astrocytes in the
human brain do not express SUCLA2 or SUCLG2
(Dobolyi et al., 2015a, 2015b); accordingly, these cells
are expected not to exhibit SUCL activity. Finally, our
recent studies show that ATP production through
mSLP can support viability and growth in the VM-
M3 glioblastoma cells (Flores et al., 2018).
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Role of SDH
SDH, also known as Respiratory Complex II, is an inte-
gral mitochondrial inner membrane protein complex that
oxidizes succinate to fumarate and transfers two elec-
trons to coenzyme Q. SDH is composed of four subunits:
SDHA, SDHB, SDHC, and SDHD. The assembly of
SDH requires two factors, SDH Assembly Factor 1
(SDHAF1) and SDHAF2 (Bardella et al., 2011).
Mutations in some of its subunits or its assembly factors
were shown to cause paragangliomas and pheochromo-
cytomas (Bardella et al., 2011). In these tumors, the
resulting inhibition of SDH increases mitochondrial
and cytosolic succinate levels, inhibiting
a‑ketoglutarate-dependent prolyl hydroxylases (PHDs),
thus causing stabilization of HIF-1a (Kurelac et al.,
2011). HIF-1a mediates much of the genetic alterations
of enzyme and transporter expressions mentioned earlier.
In this sense, succinate has been considered a proinflam-
matory oncometabolite (Selak et al., 2005; Tannahill
et al., 2013; Tretter et al., 2016). Succinate and fumarate
also inhibit other a‑ketoglutarate-dependent dioxyge-
nases, including the Jumonji‑C histone demethylases
and the TET family of 5‑methylcytosine hydroxylases,
resulting in genome-wide alterations of histone and
DNA methylation and epigenetic dysregulation (Xiao
et al., 2012). In other words, extranuclear mitochondrial
abnormalities would underlie these nuclear epigenet-
ic changes.
Although SDH mutations have not been reported in
GBM, an increase in mRNA coding for SDH subunits
has been shown in human GBM cells (Kim et al., 2015).
This is most relevant regarding mSLP because the accu-
mulation of succinate, as it may occur by high flux
through SUCL, will on one hand mediate HIF-1a
stabilization and inhibition of Jumonji‑C histone
demethylases and TET 5‑methylcytosine hydroxylases
aggravating epigenetic dysregulation, but on the other
hand, it may push the reversible SUCL reaction toward
ATP (or GTP) consumption. It is also interesting that
the interaction of SIRT5 (a lysine desuccinylase) with
cardiolipin can influence SDH activity and the efficiency
of the ETC (Zhang et al., 2017b). The cardiolipin abnor-
malities we found in murine GBM might therefore influ-
ence SIRT5 function leading to enhancement of
glutaminolysis and mSLP (Kiebish et al., 2008; Wang
et al., 2018).
Role of FH
FH converts fumarate to malate in a reversible manner.
Homozygous null mutations in the FH gene are associ-
ated with multiple cutaneous and uterine leiomyomatas
and aggressive forms of renal cell cancer (Alam et al.,
2003). Although fumarate has also been hypothesized
to inhibit PHDs, stabilization of HIF-1a was not
required for tumorigenesis in FH–/– mice (Adam et al.,
2011). Fumarate is an electrophilic unsaturated dicarbox-
ylic acid, and as such it has the ability to bind reactive
thiol residues of proteins in a process termed protein
succination (Alderson et al., 2006). Succination must
not to be confused with succinylation, the latter being a
posttranslational modification of lysine residues using
succinyl-CoA (Weinert et al., 2013). Several targets of
fumarate have now been identified, and they include
the negative regulator of NRF2, Keap1 (Ooi et al.,
2011), ACO2 (Ternette et al., 2013), and GSH (Sullivan
et al., 2013). As such, fumarate has also achieved the
status of an oncometabolite (Yang et al., 2012). As of
October 2018, FH and its role in GBM have not yet
been addressed. However, it is anticipated that accumu-
lation of fumarate, as it may occur by high flux through
SUCL performing substrate-level phosphorylation fol-
lowed by the action SDH, will mediate excessive succina-
tions, potentially contributing to tumor progression
through increased glutaminolysis (Wang et al., 2018).
Role of Adenine Nucleotide Translocase
and F0-F1 ATP Synthase in GBM
Both the ANT and the F0-F1 ATP synthase can catalyze
reversible processes. The DWm and the reversal potential
(Erev) determine the directionality of these processes, the
latter determined by the concentrations of the participat-
ing reactants (Chinopoulos, 2011a). Extramitochondrial
adenine nucleotides can contribute to matrix adenine
nucleotide pool only through the ANT and, by a minor
fraction, through the ATP-Mg/Pi carrier (Aprille, 1993).
As it has been extensively addressed in our laboratory,
substrate-level phosphorylation substantiated by succinyl
CoA ligase generating ATP assists respiration-impaired
mitochondria exhibiting diminished values of DWm to
retain high matrix ATP levels, sparing cells from cytosol-
ic/nuclear ATP consumption (Chinopoulos, 2011a,
2011b). This concept is inherently related to tumor
metabolism generally and to GBM metabolism specifi-
cally, as the likelihood is high that GBM mitochondria
exhibit diminished values of DWm due to cristolysis and
respiratory inhibition. Pinpointing the component(s) of
the respiratory chain exhibiting defects leading to a
decrease in respiratory capacity is a daunting task. This
task is further complicated by the fact that the exact site
of the defect in the respiratory chain will dictate whether
a cell can be rescued by provision of substrates support-
ing mSLP (Chinopoulos, 2018). In any case, respiratory
arrest and ensuing decrease in DWm would result in con-
sumption of matrix ATP by the reverse-operating F0-F1
ATP synthase. The generation of matrix ATP by succinyl
CoA ligase is instrumental in rescuing cancer cells from
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cytosolic ATP consumption. On the same line of thought,
the ATPase Inhibitory Factor 1 exhibits stark changes in
expression among various types of human carcinomas
(Sanchez-Arago et al., 2013) and has been linked to
energy metabolism reprogramming, signaling the onco-
genic phenotypes of cancer (Formentini et al., 2012). The
critical information that can be obtained from this con-
sideration is that substrate-level phosphorylation sub-
stantiated by succinyl CoA ligase generating ATP in
the matrix assists respiration-impaired mitochondria
that exhibit diminished values of DWm in avoiding cyto-
solic ATP consumption, thus sparing cells from cytosol-
ic/nuclear ATP depletion. This concept is inherently
related to tumor metabolism because cancer mitochon-
dria frequently exhibit diminished values of DWm, a con-
cept associated with the reverse operation of the F0-F1
ATP synthase and the consumption of matrix ATP.
From the above considerations, we have come to sev-
eral insights regarding GBM metabolism from the earlier
information: (a) The net balance of cytosolic ATP pro-
duction is low despite having a high rate of glycolysis due
to diminished production by the payoff phase substanti-
ated by the reaction catalyzed by PKM2. (b) ATP is
needed in the cytosol not only for maintenance of mem-
brane ion pumps but also for ATP-consuming reactions
of fatty acid synthesis. (c) The mitochondrial F0-F1 ATP
synthase becomes an ATP consumer in pumping protons
out of the matrix due to defects in the ETC.
Consequently, little ATP is generated from either glycol-
ysis or OxPhos, which increases the danger of mitochon-
dria becoming net ATP consumers. (d) The branch of the
citric acid cycle toward citrate formation becomes dimin-
ished due to lack of intramitochondrial catabolism of
pyruvate. On the other hand, the rate of glutamine catab-
olism toward the citric acid cycle becomes high. (e) The
obligate metabolites formed by this pathway are a-keto-
glutarate, succinyl-CoA, and succinate. (f) This metabo-
lite trio implies significant ATP (or GTP) synthesis
through SUCL-mediated substrate-level phosphoryla-
tion. Maintenance of a high matrix ATP/ADP ratio
also assures that the ANT provides ATP to the cytosol
while also preventing the F0-F1 ATP synthase from
draining cytosolic ATP reserves. The concomitant forma-
tion of succinate is efficiently shuttled outside the mito-
chondria but can also be metabolized to fumarate and
malate, the latter supporting exchange of other metabo-
lites across the inner mitochondrial membrane. An
important question is whether other metabolites that
converge on succinyl-CoA can also support ATP produc-
tion in the mitochondrial matrix. This is addressed in the
following section and in Figure 3. We also recognize that
our views might be considered as a conjecture until addi-
tional evidence is obtained to support our position.
Convergence of Metabolites Toward
Succinyl-CoA and mSLP
There are a number of metabolites that catabolize
toward the citric acid cycle through succinyl-CoA, thus
leading to ATP (or GTP) formation through SUCL.
Our review of the relevant biochemistry, however,
shows that only glutamine catabolism can yield a net
ATP (or GTP) production though mSLP. As shown in
Figure 3, several metabolites eventually converge toward
succinyl-CoA including the amino acids valine, isoleu-
cine, methionine, histidine, threonine, glutamine, gluta-
mate, and also propionate (Todesco et al., 1991; Laurent
et al., 1995; Wong et al., 2006; Snyder et al., 2015) and
thymine (Stryer, 1995), and odd-chain fatty acids (OC-
FAs). Except for glutamate and glutamine, however, the
catabolism of all other metabolites expends one or more
high-energy phosphates during metabolic interconver-
sions before becoming succinyl-CoA. Support for
mSLP can also come from conversion to glutamate
(such as proline and arginine) or from other metabolites
that catabolize toward a-ketoglutarate (such as glycine,
serine, sarcosine, dimethylglycine through pyruvate, and
fatty acids or leucine through acetyl-CoA). However, the
concentrations of these metabolites in the plasma or in
the microenvironment are far lower than that of gluta-
mine and are therefore unlikely to make a major contri-
bution to mSLP (Yang et al., 2017). Dashed arrows in
Figure 3 imply multiple enzymatic steps (omitted for the
sake of clarity).
In addition to the pathways converging toward
succinyl-CoA, there are two more ways for producing
high-energy phosphates at the substrate level: first
through the mitochondrial phosphoenolpyruvate
carboxykinase, interconverting PEP and GDP to oxalo-
acetate and GTP (GTP, GDP, ADP, and ADP can
interconvert through nucleoside diphosphate kinase iso-
forms) and second through the monofunctional
C1-tetrahydrofolate (THF) synthase interconverting
ADP, phosphate, and 10-formyltetrahydrofolate to
ATP, formate, and THF. However, the mitochondrial
phosphoenolpyruvate carboxykinase reaction is strongly
favored toward PEP formation (thus consuming GTP) in
a process called pyruvate recycling pathway (Freidmann
et al., 1971; Rognstad and Katz, 1972; Cohen, 1987;
Cerdan et al., 1990; Kunnecke et al., 1993; Bakken
et al., 1997a, 1997b; Haberg et al., 1998; Chinopoulos,
2013). For this pathway, PEP enters mitochondria
through a phosphate/PEP antiporter (McCoy and
Doeg, 1975), a protein with isoforms in members C, D,
and E of the solute carrier family 35 (Venter et al., 2001;
Gerhard et al., 2004; Ota et al., 2004; Skarnes et al.,
2011). Finally, carboxylation of pyruvate by PC yielding
oxaloacetate is a thermodynamically reversible reaction;
however, backflow toward pyruvate leading to ATP
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production may occur only at a very low rate (Freidmann
et al., 1971; McClure et al., 1971a, 1971b; Barden et al.,
1972). Consumption of one ATP in the reaction cata-
lyzed by PC is also the reason why metabolites that con-
verge to pyruvate (glycine, serine, sarcosine, and
dimethylglycine) do not yield net ATP (or GTP) from
mSLP. To date, the contribution of monofunctional
C1-THF synthase on yielding ATP through substrate-
level phosphorylation has not been adequately addressed.
According to our analysis, glutamine would be the prime
driver of mSLP and ATP production through SUCL.
Evidence for our hypothesis was recently obtained from
studies of the murine VM-M3 glioblastoma cells grown
under hypoxia (Flores et al., 2018).
Interactions Between Oxidative
Decarboxylation, Provision of Reducing
Equivalents, Reductive Carboxylation,
and mSLP
From the earlier considerations, it is evident that only
catabolism of glutamine or glutamate may lead to net
ATP (or GTP) production through mSLP; this is entirely
Figure 3. Pathways leading to ATP (or GTP) generation at the substrate level. Dashed arrows imply multiple enzymatic steps (omitted for
clarity). Reduction of NADþ to NADH by PDH is omitted for uncluttering the figure.
a-Kg¼ a-ketoglutarate; ACSS1¼ acetyl-coenzyme A synthetase 2-like, mitochondrial; BCKDH¼ branched-chain a-ketoacid dehydroge-
nase; GLSc¼ glutaminase, cytosolic; GLSm¼ glutaminase, mitochondrial; GLUD¼ glutamate dehydrogenase; GOT2¼ aspartate amino-
transferase; KGDHC¼ a-ketoglutarate dehydrogenase complex; MTHFD1L¼monofunctional C1-tetrahydrofolate synthase;
NME¼ nucleoside diphosphate kinase; OC-FA¼ odd-chain fatty acid; Pi¼ inorganic phosphate; PPi¼ pyrophosphate; PC¼ pyruvate car-
boxylase; PDH¼ pyruvate dehydrogenase; PEP¼ phosphoenolpyruvate; PEPCKm¼mitochondrial phosphoenolpyruvate carboxykinase;
PK¼ pyruvate kinase; SAM¼ S-adenosylmethionine; SDH¼ succinate dehydrogenase; SDS¼ serine dehydratase; SUCL¼ succinate-CoA
ligase; THF¼ tetrahydrofolate.
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consistent with the extremely high glutamine dependence
of many tumors including GBM. However, this prompts
considering the following two concepts: (a) reductive car-
boxylation of glutamine toward citrate that exits mito-
chondria and is destined for fatty acid synthesis has been
well-documented to occur in cancers (Gaude et al., 2018),
and especially in GBM (DeBerardinis et al., 2007; Ta and
Seyfried, 2015) and (b) oxidative decarboxylation of
glutamine/glutamate toward mSLP substantiated by
SUCL demands stable provision of NADþ for
KGDHC. Reductive carboxylation versus oxidative
decarboxylation of glutamine/glutamate will branch out
at the level of a-ketoglutarate, depicted in Figure 4; in the
former case, it will become isocitrate by the NADPþ-
dependent IDH2 and then citrate through reversal of
ACO2; in the latter case, a-ketoglutarate will become
Figure 4. Provision of NADþ in the matrix of mitochondria in the absence of OxPhos. Enzyme annotations as in Figures 2 and 3.
a-Kg¼ a-ketoglutarate; ACO2¼ aconitase; ACLY¼ATP citrate lyase; FA¼ fatty acid; FAD¼ flavin adenine dinucleotide;
GLSc¼ glutaminase, cytosolic; GLSm¼ glutaminase, mitochondrial; GLUD¼ glutamate dehydrogenase; GOT2¼ aspartate aminotrans-
ferase; IDH2¼NADPþ-dependent isocitrate dehydrogenase; KGDHC¼a-ketoglutarate dehydrogenase complex; MDH¼malate dehy-
drogenase; NME¼ nucleoside diphosphate kinase; SDH¼ succinate dehydrogenase; SUCL¼ succinate-CoA ligase.
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succinyl-CoA by KGDHC and thus follow mSLP.
Although both pathways start from a-ketoglutarate,
they are not mutually exclusive; flux of glutamine/gluta-
mate toward a-ketoglutarate is sufficiently high to sup-
port both pathways (Pike Winer and Wu, 2014; Yang
et al., 2017). Interestingly, it was recently shown that in
cancer cell lines, the degree of OxPhos defects conferred
by mtDNA mutations dictates whether a-ketoglutarate
follows oxidative decarboxylation or reductive carboxyl-
ation (Chen et al., 2018; Chinopoulos, 2018). On the
other hand, regarding oxidative decarboxylation in the
absence of OxPhos during which the ability of Complex
I in providing NADþ is impaired, it has been shown that
intramitochondrial diaphorases can contribute to the
matrix NADþ pool (Kiss et al., 2014). This reaction
was, however, demonstrated only in isolated mitochon-
dria in artificial conditions. It is currently not known how
mitochondria in situ regenerate NADþ in the absence of
OxPhos; it is not even known if a residual, minimal
remaining function of Complex I during hypoxia/
anoxia is sufficient for providing NADþ for KGDHC
for supporting mSLP, in view of the fact that overall
respiration has ceased. Apart from mitochondrial dia-
phorases, there are other pathways that can adopt this
role; as shown in Figure 4, the malate-aspartate shuttle
can operate in reverse (Bremer and Davis, 1975;
Chouchani et al., 2014) and lead to a decrease in the
matrix NADH/NADþ ratio. For example, conditions
that can lead to excessive NADH oxidation in the cytosol
may lead to increased formation of oxaloacetate in the
same compartment that will in turn lead to transamina-
tion with glutamate to aspartate and a-ketoglutarate; this
will cause the exchange of cytosolic a-ketoglutarate with
mitochondrial malate, shifting the equilibrium of MDH2
toward NADH oxidation, thus yielding NADþ in the
matrix. Furthermore, salvage reactions that can lead to
NADþ formation could also play a role (Yang and
Sauve, 2016). Moreover, there are other potential intra-
mitochondrial reactions that can lead to a decrease in
matrix NADH/NADþ ratio, such as those participating
in THF metabolism (Yang and Vousden, 2016). The
group of Vamsi Mootha has published a compendium
of 342 reactions utilizing NAD(P)H, termed the NAD
(P)ome (Goodman et al., 2018). Hence, there are likely
several mechanisms by which cancer cells can obtain
NADþ in low-oxygen, hyper-reducing conditions.
The Warburg Theory Revisited
It is our view that SUCL can provision ATP (or GTP),
thus bailing-in cancer mitochondria from a reverse-
operating F0-F1 ATP synthase when ETC function(s)
are impaired but can also assist glycolysis in providing
high-energy phosphates for energy-consuming processes.
This mechanism has been previously suggested and is
pertinent to GBM and other solid tumors with hypoxic
centers (Seyfried and Shelton, 2010; Seyfried, 2012d;
Seyfried et al., 2017). Relevant to this, computer model-
ing of cancer metabolism predicted that a repression of
SUCL would cause a significant reduction in growth rate,
relative to known chemotherapeutic targets (Khazaei
et al., 2012). It has also not escaped our attention that
mSLP could represent the missing link in Warburg’s cen-
tral theory that OxPhos insufficiency with compensatory
fermentation is the origin of cancer. In addition to cyto-
plasmic substrate-level phosphorylation, that is, aerobic
fermentation or the Warburg effect, mSLP could also
compensate for insufficient or defective OxPhos, as we
have described in this review. Unfortunately, the role of
glutamine and mSLP was unknown to Warburg.
Although most investigators have focused on aerobic
fermentation (Warburg effect), we find it astonishing
that almost all of the major reviews or previous studies
on cancer energy metabolism have not addressed or
even recognized the role of SUCL activity and mSLP,
as a compensatory energy mechanism for deficient
OxPhos. Based on our views, mSLP could become a
key mechanism for energy production in tumor cells
with defective respiration or for growth in hypoxic
environments.
Confusion over the linkage of OxPhos to oxygen con-
sumption and a general failure to recognize the role of
mSLP as a compensatory energy mechanism have led
many investigators to think that the ETC is normal in
GBM and in other tumors. Further confusion could
come in part from observations that GBM and other
tumors might also use fatty acids and ketone bodies for
growth (Bonuccelli et al., 2010; Baenke et al., 2013;
Pascual et al., 2017; Xia et al., 2017; Jia et al., 2018).
Fats and ketone bodies, however, are nonfermentable
fuels and would require oxidative respiration for energy
generation. Recent studies show, however, that fats can
upregulate glycolysis and glutaminolysis through uncou-
pling mechanisms (Samudio et al., 2009; Valle et al.,
2010; Vozza et al., 2014). Enhanced glucose and gluta-
mine metabolism could therefore be an indirect effect of
high-fat diets that are consumed in unrestricted amounts
(Zhou et al., 2007). The numerous abnormalities in the
number, structure, and function of GBM mitochondria
mentioned earlier would be expected to alter the function
of the ETC according to the predictions of Lehninger
(1964) and Ferreria (2010). Little ATP produced from
glycolysis might also be expected for those tumors
(GBM) where the dimeric PKM2 expression predomi-
nates over PKM1 expression. In light of the PKM2
issue, the convergence of metabolites toward succinyl-
CoA and mSLP could provision sufficient ATP to main-
tain growth of GBM and possibly other tumors in
hypoxic environments. As glutamine would be the
major metabolite for provisioning ATP synthesis through
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mSLP under normoxic or hypoxic conditions in tumor
cells, the phenomenon could be considered aWarburg Q-
Effect to distinguish this effect from that involving the
aerobic fermentation of glucose. Both effects arise from
compromised OxPhos. Emerging evidence indicates that
the mitochondrial metabolic theory can explain better the
hallmarks of cancer than can the somatic mutation
theory (Seyfried and Shelton, 2010; Seyfried, 2012d;
Seyfried et al., 2014; Seyfried, 2015). Recognition of
mSLP as a second major compensatory energy mecha-
nism for tumor cells with defective or insufficient OxPhos
could have profound implications for managing most
tumors including GBM.
Considerations for Controlling GBM
Cell Growth
It is widely recognized that glucose and glutamine are the
major energy metabolites that drive GBM growth and
invasion. Glucose and glutamine become the major fer-
mentable fuels for heterogeneous GBM cells due to the
inability of OxPhos to meet energy demands and for
growth in hypoxic environments. Recent findings indi-
cate that glutamine is the major fuel for GBM cells
with mesenchymal molecular subtype, whereas glucose
in the major fuel for GBM cells with proliferative subtype
(Oizel et al., 2017). According to our concepts based on
the underlying biochemistry discussed earlier, control of
GBM cell growth could involve the simultaneous target-
ing of substrate-level phosphorylation reactions in the
cytoplasm (glycolysis) and in the mitochondria (glutami-
nolysis). Although we do not make any recommenda-
tions for treatment of GBM in patients, a parsimonious
consideration would be to restrict availability of glucose
and glutamine to the tumor cells to downregulate both
glycolysis and glutaminolysis simultaneously. This
approach was shown to kill GBM and HeLa cells in
vitro (Shelton, 2010; Mathews et al., 2014), as would be
predicted from ensemble modeling of cancer metabolism
(Khazaei et al., 2012). No cell can grow without energy
regardless of its genetic composition. Because ketone
bodies can replace glucose as an energy source, prior
studies show that glucose levels could be significantly
reduced without harmful effects after first transitioning
the body to therapeutic ketosis (Drenick et al., 1972;
Seyfried et al., 2015; Seyfried et al., 2017). This fact
was mentioned in the work of Cahill and Veech (2003)
and was demonstrated in nine persons who received insu-
lin injection after fasting for 2 months (Drenick et al.,
1972). Indeed, the blood glucose level in one person in
the insulin group reached as low as 9 mg/dl (0.5 mmol/l)
without evidence of a hypoglycemic response (Drenick
et al., 1972). These findings suggest that the glucose
needed for GBM cell growth could be majorly restricted
under therapeutic ketosis.
Ketone bodies also possess anti-inflammatory poten-
tial through reduction of reactive oxygen species and
increase of GSH peroxidase activity in normal brain
cells (Veech, 2004; Seyfried and Mukherjee, 2005).
Some studies have shown that GBM and other malignant
brain tumors may have a reduced ability to utilize ketone
bodies due in part to diminished activity of succinyl-
CoA:3-ketoacid coenzyme A transferase 1, which is
essential for metabolism of ketone bodies (Fredericks
and Ramsey, 1978; Zhou et al., 2007; Maurer et al.,
2011). Glucose restriction under therapeutic ketosis or
calorie restriction will downregulate the entire glycolytic
pathway from glucose to pyruvate (Marsh et al., 2008).
Glycolytic downregulation will not only deprive tumor
cells of growth metabolites but will also reduce LDHA
activity and lactate production, thus reducing angiogen-
esis and inflammation in the tumor microenvironment
(Mukherjee et al., 2002, 2004; Marsh et al., 2008;
Mulrooney et al., 2011; Urits et al., 2012; Husain et al.,
2013; Vergati et al., 2017). Glucose restriction should
also reduce the metabolites needed for serine-derived
one-carbon metabolism, which would further reduce
tumor cell antioxidant capacity and growth (Meiser and
Vazquez, 2016; Semenza, 2017; Zhang et al., 2017a). We
also found that calorie restriction and restricted ketogen-
ic diets, which lower blood glucose and elevate blood
ketone bodies are proapoptotic against murine glioblas-
toma and neural stem cell tumors (Mukherjee et al., 2002,
2004; Shelton et al., 2010a). Glucose targeting would also
reduce metabolites generated through the pentose phos-
phate pathway that would be needed for the synthesis of
GSH and growth metabolites.
From the biochemical point of view, catabolism of
ketone bodies obligatorily bypasses mSLP. As shown in
Figure 5, the ketone bodies acetoacetate and b-hydroxy-
butyrate enter mitochondria and eventually the citric acid
cycle as succinate, bypassing mSLP. This is because for-
mation of succinate is not through SUCL but through
succinyl-CoA:3-ketoacid coenzyme A transferase 1. By
doing so, catabolism of both acetoacetate and
b-hydroxybutyrate does not lead to the formation of
high-energy phosphates through mSLP. Furthermore,
b-hydroxybutyrate is expected to decrease mSLP through
glutamine/glutamate even further because it increases
NADH/NADþ ratio, thus hindering KGDHC operation
(Kiss et al., 2013, 2014). It is also essential to target glu-
cose and glutamine together, as glutamine can be synthe-
sized from glucose-derived glutamate through the
glutamine synthetase activity (Tardito et al., 2015).
Hence, the simultaneous restriction of glucose and gluta-
mine, while under therapeutic ketosis, could halt growth
of GBM cells that are more dependent on substrate-level
phosphorylation than on OxPhos for survival.
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It is important to mention that the targeting of gluta-
mine is more challenging than is the targeting of glucose
for GBM growth control. Glutamine, like glucose, is an
essential metabolite for the neoplastic cells of GBM.
Unlike glucose, however, glutamine is also an essential
metabolite for cells of the gut, the immune system, and
for general physiological homeostasis (Souba, 1993;
Newsholme, 2001; Young and Ajami, 2001).
Consequently, glutamine targeting must be done careful-
ly so as not to harm normal cell function or disrupt phys-
iological homeostasis.
We recently proposed a press-pulse therapeutic strate-
gy for managing most cancers including GBM while min-
imizing toxicity to normal cells and tissues (Seyfried
et al., 2017). The press-pulse concept was developed
from the field of paleobiology in showing that the extinc-
tion of organisms during prior evolutionary epochs
occurred in the ecosystem only when a chronic press dis-
turbance coincided with an acute pulse disturbance. In
our adaption of this concept for the cancer problem,
press therapies are designed to reduce systemic glucose
availability while elevating blood levels of ketone bodies,
which tumor cells cannot effectively use for energy gen-
eration. This approach is designed to pit the metabolic
demands of normal cells against those of the mutated
tumor cells, which are less capable than normal cells in
adapting to metabolic stress from nutrient deprivation
due to accumulation of tumor mutations (Seyfried and
Mukherjee, 2005; Seyfried et al., 2017). Ketone body
supplements could further reduce glucose levels while
Figure 5. Ketone bodies bypass mSLP. Enzyme annotations as for Figures 2, 3, and 4.
BDH¼ b-hydroxybutyrate dehydrogenase; FAD¼ flavin adenine dinucleotide; GLSc¼ glutaminase, cytosolic; GLSm¼ glutaminase, mito-
chondrial; GLUD¼ glutamate dehydrogenase; GOT2¼ aspartate aminotransferase; KGDHC¼a-ketoglutarate dehydrogenase complex;
NME¼ nucleoside diphosphate kinase; OXCT1¼ succinyl-CoA:3-ketoacid coenzyme A transferase 1; PC¼ pyruvate carboxylase;
PDH¼ pyruvate dehydrogenase; PEP¼ phosphoenolpyruvate; PK¼ pyruvate kinase; SUCL¼ succinate-CoA ligase.
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enhancing the respiratory energy metabolism in normal
cells. Stress management techniques together with exer-
cise could further reduce blood glucose levels while
improving general health. The press therapies would be
designed to work synergistically with acute pulse
therapies to further target glucose and glutamine metab-
olism. Pulse therapies would involve drug cocktails
and procedures that work synergistically with the press
therapy to gradually degrade and eradicate the tumor
cells. The drugs chosen would target simultaneously gly-
colysis in the cytoplasm and substrate-level phosphory-
lation in the mitochondria. Hence, diets, drugs, and
procedures that restrict availability of glucose and gluta-
mine could deprive GBM cells of the fuels necessary for
growth while avoiding damage to normal cells of the
brain and body.
Conclusions
We review evidence that describes abnormalities in the
number, structure, and function of mitochondria in
GBM. These abnormalities, together with expression of
the PKM2 isoform, would compromise effective energy
production through OxPhos and glycolysis, respectively.
We also describe a framework for how provision of high-
energy phosphates through mSLP in GBM could com-
pensate for the loss of energy production through both
glycolysis and OxPhos. A reliance on mSLP using glu-
cose through cytoplasmic glycolysis and glutamine
through glutaminolysis will cause the cancer cells to
enter their default state of unbridled proliferation, that
is, the state of existence for all cells prior the emergence
of atmospheric oxygen (Szent-Gyorgyi, 1977;
Sonnenschein and Soto, 2000; Seyfried and Shelton,
2010). The unbridled proliferation of GBM cells should
not be viewed as a growth advantage but rather as a
pathological phenotype arising from defective OxPhos
with compensatory substrate-level phosphorylation
occurring in the cytoplasm and in the mitochondria
(Seyfried, 2012a; Seyfried et al., 2017). The simultaneous
restriction of glucose and glutamine, while under thera-
peutic ketosis, will deprive GBM cells of substrates for
growth and energy production. This information should
have value in the clinic.
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